Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.

• DOI: 10.17615/tc7d-x473
• Publication Date: 2023-04-18
• Authors: Mark A. Marzinke; Jessica M. Fogel; Zhe Wang; Estelle Piwowar-M...; Ryan Kofron; Amber Moser; Pradip Bhandari; Ryann Gollings; Lane R. Bushman; Lei Weng; Elias K. Halvas; John Mellors; Peter L. Anderson; Deborah Persaud; Craig W. Hendrix; Marybeth McCauley; Alex R. Rinehart; Marty St Clair; Susan L. Ford; James F. Rooney; Adeola Adeyeye; Suwat Chariyalertsak; Kenneth Mayer; Roberto C. Arduino; Myron S. Cohen; Beatriz Grinsztejn; Brett Hanscom; Raphael J. Landovitz; Susan H. Eshleman
• Keywords: Male; TDF-FTC; Anti-HIV Agents; Clinical Sciences; preexposure prophylaxis; men who have sex with men; HIV Infections; Sexual and Gender Minorities (SGM/LGBT*); Microbiology; Antiviral Agents; Transgender Persons; prevention; Humans; Emtricitabine; Tenofovir; Retrospective Studies; 360; injectable; Biomedical and Clinical Sciences; Prevention; cabotegravir; Evaluation of treatments and therapeutic interventions; HIV; long-acting; Pharmacology and Pharmaceutical Sciences; Medical microbiology; 3. Good health; Health Disparities; Infectious Diseases; Good Health and Well Being; Pharmacology and pharmaceutical sciences; Medical Microbiology; 6.1 Pharmaceuticals; Sexually Transmitted Infections; HIV/AIDS; Female; Pre-Exposure Prophylaxis; Infection; HPTN 083

HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm).